Is compounded semaglutide safe - what you need to know

Introduction

Compounded semaglutide is not FDA-approved and does not undergo the same manufacturing, purity, or potency testing as brand-name Ozempic or Wegovy. It is available from compounding pharmacies at roughly $178 per month compared to $935–1,350 per month for brand-name versions, which makes it appealing to people without insurance coverage. However, the FDA has received adverse outcome reports tied to compounded products, and the legal landscape shifted in late 2024 when the official semaglutide shortage was resolved. Here is what you need to understand before making a decision.

What compounded semaglutide actually is

Compounding pharmacies create custom drug preparations by mixing active pharmaceutical ingredients (APIs) according to a prescriber’s order. This is a legal and long-standing practice in U.S. healthcare, commonly used to adjust dosage forms or remove allergens. Compounded semaglutide typically uses semaglutide sodium salt rather than the semaglutide base used in FDA-approved products. The resulting formulation has not been evaluated by the FDA for safety, efficacy, or bioequivalence.

Unlike brand-name medications manufactured by Novo Nordisk under strict FDA-regulated Good Manufacturing Practices (cGMP), compounded preparations are regulated at the state level with oversight from state pharmacy boards. The quality, purity, and potency of compounded semaglutide are not verified to the same standards as commercially available versions.

Why compounded semaglutide became popular

The surge in demand for GLP‑1 medications created widespread supply shortages beginning in 2022. During a declared drug shortage, Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to produce copies of commercially available drugs. This exception gave compounding pharmacies legal footing to produce semaglutide preparations while the shortage was active.

Cost was the other major driver. Brand-name Wegovy carries a list price of approximately $1,350 per month, and Ozempic runs about $935 per month without insurance. Many patients found that their insurance denied coverage for weight-loss indications or imposed step therapy requirements. Compounded semaglutide at roughly $178 per month filled the gap for people who could not afford or access brand-name options.

The safety concerns

The FDA has issued multiple warnings about compounded semaglutide products. The agency has received adverse outcome reports including dosing errors, sterility failures, and reactions potentially linked to impurities or incorrect concentrations. Key concerns include:

• No bioequivalence testing: Compounded products are not required to demonstrate that they deliver the same blood levels of semaglutide as FDA-approved versions. The semaglutide sodium salt used by many compounders has different molecular properties than the semaglutide base in Ozempic and Wegovy.
• Variable quality: A 2023 FDA analysis of compounded semaglutide samples found that some contained incorrect amounts of the active ingredient. Without standardized testing, patients cannot be certain they are receiving a consistent dose.
• Sterility risks: Injectable medications require strict sterile manufacturing. Not all compounding pharmacies maintain the same level of clean-room infrastructure as large-scale pharmaceutical manufacturers.
• No clinical trial data: The specific formulations produced by compounding pharmacies have not been studied in clinical trials, so their efficacy and side effect profiles are not well characterized.

What changed in late 2024

In October 2024, the FDA removed semaglutide from its drug shortage list after Novo Nordisk confirmed adequate commercial supply. This was significant because the legal basis for compounding copies of brand-name drugs under Section 503A depends on an active shortage declaration. With the shortage resolved, the FDA’s position is that compounding pharmacies should no longer produce semaglutide copies when commercially manufactured versions are available.

Several compounding pharmacies challenged the FDA’s determination in court, and litigation is ongoing. The legal landscape remains uncertain, but patients should be aware that the regulatory environment has shifted and future access to compounded semaglutide may be restricted.

Questions to ask before using compounded semaglutide

If you are considering a compounded product, discuss these points with your prescriber:

• Pharmacy accreditation: Is the compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) or registered as a 503B outsourcing facility with the FDA? 503B facilities face more rigorous federal oversight than standard 503A pharmacies.
• Third-party testing: Does the pharmacy conduct independent testing for potency, sterility, and endotoxins on each batch?
• Ingredient sourcing: Where does the pharmacy source its semaglutide API? Is the supplier FDA-registered?
• Prescriber experience: Has your provider prescribed compounded GLP‑1 medications before, and do they have a monitoring plan for you?

These questions do not eliminate risk, but they help distinguish higher-quality compounding operations from less regulated ones.

Brand-name alternatives for reducing cost

Before turning to compounding, explore these options for accessing FDA-approved semaglutide:

• Manufacturer savings programs: Novo Nordisk offers savings cards that can reduce out-of-pocket costs for commercially insured patients.
• Prior authorization appeals: If your insurance initially denies coverage, your provider can submit a prior authorization with supporting documentation of medical necessity.
• Patient assistance programs: Novo Nordisk’s PAP provides free medication to qualifying uninsured or underinsured patients.
• Tirzepatide as an alternative: Eli Lilly’s Mounjaro and Zepbound (tirzepatide) may have different insurance coverage and savings program availability.

Track your treatment with Shotsy

Regardless of whether you use brand-name or compounded semaglutide, Shotsy tracks your doses, weight, and side effects in one place. Documented tracking data is especially important with compounded products, where batch-to-batch variability means closer monitoring helps you and your provider catch irregularities early.

Conclusion

Compounded semaglutide offers significant cost savings but comes with real trade-offs in quality assurance, regulatory oversight, and legal certainty. It is not FDA-approved, its purity and potency are not verified to the same standards as brand-name products, and the legal basis for compounding shifted after the semaglutide shortage resolved in late 2024. If you choose a compounded product, select an accredited pharmacy, ask about third-party testing, and track your response closely. Discuss the risks and benefits with your healthcare provider to make an informed decision that fits your situation.